Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05764720 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05764720 · ClinicalTrials.gov record · last posted 2026-03-16

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

Study acronym: ARTIA-Pancreas
StatusRecruiting
PhaseNot applicable
Started2023-05-14
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2023-03-07; most recent amendment 2026-03-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT05764720
Lead Sponsor Varian, a Siemens Healthineers Company
Collaborators: Washington University School of Medicine
Conditions Pancreatic Cancer
Enrollment 134 participants
Start Date 2023-05-14
Primary Completion 2028-03 (estimated)
Study Completion 2030-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-16